Oppenheimer analyst Kristen Owen last night initiated coverage of Mosaic (MOS) with a Perform rating and no price target Amid weakened soft commodity prices and supply constraints, affordability remains a challenge for certain nutrition products, particularly phosphates, the analyst tells investors in research note. The firm sees a modestly more favorable affordability backdrop coming into 2025 helping to spur demand recovery, but is anticipating Mosaic’s volumes to remain below historical application trend lines. As such, its views the stock’s risk/reward as balanced.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.